Prudential Financial
CAPR icon

Prudential Financial’s Capricor Therapeutics CAPR Stock Holding History

Prudential Financial’s Portfolio CAPR Stock Details CAPR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$211K Sell
8,760
-15,670
-64% -$475K ﹤0.01% 2213
2026
Q1 		$743K Buy
+24,430
New +$651K ﹤0.01% 1706
2024
Q2 		– Sell
-10,000
Closed -$67.9K – 2709
2024
Q1 		$67.9K Buy
+10,000
New +$48.4K ﹤0.01% 2566

Other funds holding CAPR

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BCM
Boxer Capital Management San Diego, California $1.33B AUM 864.5% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Prudential Financial's CAPR Position: Q2 2026 in Review

Prudential Financial reduced its Capricor Therapeutics (CAPR) stake by 64% in Q2 2026, selling an estimated $475K and leaving 8,760 shares worth $211K. The position accounts for ﹤0.01% of the portfolio, ranked #2213.

Prudential Financial first reported a position in CAPR in Q1 2024 and has held it in 3 quarters since. The position peaked at $743K in Q1 2026. 170 funds tracked by Wall St. Rank hold CAPR as of Q2 2026.

  • Prudential Financial held 8,760 shares of Capricor Therapeutics worth $211K as of Q2 2026.
  • Prudential Financial sold 15,670 Capricor Therapeutics shares in Q2 2026, an estimated $475K.
  • Capricor Therapeutics made up ﹤0.01% of Prudential Financial's portfolio in Q2 2026, its #2213 holding.
  • Prudential Financial first reported a position in Capricor Therapeutics in Q1 2024 and has held it in 3 quarters since.
  • Prudential Financial's Capricor Therapeutics position peaked at $743K in Q1 2026.
  • 170 funds tracked by Wall St. Rank held Capricor Therapeutics as of Q2 2026.

Based on Prudential Financial's 13F filing for Q2 2026, filed 12 Aug 2026.